Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Invests $2.46 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $2,457,000. Syndax Pharmaceuticals accounts for about 1.3% of Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group's investment portfolio, making the stock its 18th biggest position. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group owned 0.23% of Syndax Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. CWM LLC grew its holdings in Syndax Pharmaceuticals by 795.2% during the first quarter. CWM LLC now owns 23,374 shares of the company's stock worth $287,000 after buying an additional 20,763 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $295,000. Bank of New York Mellon Corp raised its holdings in shares of Syndax Pharmaceuticals by 2.5% in the first quarter. Bank of New York Mellon Corp now owns 229,758 shares of the company's stock valued at $2,823,000 after purchasing an additional 5,497 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Syndax Pharmaceuticals during the first quarter valued at about $162,000. Finally, Rhumbline Advisers boosted its holdings in Syndax Pharmaceuticals by 6.5% during the first quarter. Rhumbline Advisers now owns 120,810 shares of the company's stock worth $1,484,000 after purchasing an additional 7,361 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have commented on SNDX. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. Scotiabank boosted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, July 10th. They issued a "buy" rating and a $18.00 price objective for the company. UBS Group lowered their target price on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday. Finally, Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.10.

Insider Buying and Selling

In other news, CEO Michael A. Metzger sold 7,534 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $9.29, for a total transaction of $69,990.86. Following the sale, the chief executive officer directly owned 298,661 shares in the company, valued at $2,774,560.69. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 4.10% of the stock is currently owned by corporate insiders.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX traded down $0.21 during trading on Friday, hitting $9.46. 1,900,856 shares of the company's stock traded hands, compared to its average volume of 1,868,549. The company has a debt-to-equity ratio of 1.53, a quick ratio of 5.75 and a current ratio of 5.80. The stock has a market capitalization of $814.03 million, a price-to-earnings ratio of -2.45 and a beta of 0.70. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07. The business has a 50 day moving average of $9.88 and a 200-day moving average of $12.18.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.06. Syndax Pharmaceuticals had a negative net margin of 757.53% and a negative return on equity of 101.60%. The company had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. During the same period last year, the firm earned ($0.85) EPS. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% on a year-over-year basis. As a group, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).